journal
MENU ▼
Read by QxMD icon Read
search

Lancet Respiratory Medicine

journal
https://www.readbyqxmd.com/read/28094141/intravenous-zanamivir-or-oral-oseltamivir-for-hospitalised-patients-with-influenza-an-international-randomised-double-blind-double-dummy-phase-3-trial
#1
Francisco M Marty, Joan Vidal-Puigserver, Carol Clark, Sandeep K Gupta, Esperanza Merino, Denis Garot, Marianne J Chapman, Frédérique Jacobs, Eduardo Rodriguez-Noriega, Petr Husa, Denise Shortino, Helen A Watson, Phillip J Yates, Amanda F Peppercorn
BACKGROUND: Neuraminidase inhibitors are effective for the treatment of acute uncomplicated influenza. However, there is an unmet need for intravenous treatment for patients admitted to hospital with severe influenza. We studied whether intravenous zanamivir was a suitable treatment in this setting. METHODS: In this international, randomised, double-blind, double-dummy, phase 3 trial, we recruited patients aged 16 years or older with severe influenza admitted to 97 hospitals from 26 countries...
January 13, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28094140/corrections
#2
(no author information available yet)
No abstract text is available yet for this article.
January 13, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28094139/theranostics-in-severe-influenza
#3
Jordi Rello
No abstract text is available yet for this article.
January 13, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28087362/clinical-phenotypes-and-outcomes-of-heritable-and-sporadic-pulmonary-veno-occlusive-disease-a-population-based-study
#4
David Montani, Barbara Girerd, Xavier Jaïs, Marilyne Levy, David Amar, Laurent Savale, Peter Dorfmüller, Andrei Seferian, Edmund M Lau, Mélanie Eyries, Jérôme Le Pavec, Florence Parent, Damien Bonnet, Florent Soubrier, Elie Fadel, Olivier Sitbon, Gérald Simonneau, Marc Humbert
BACKGROUND: Bi-allelic mutations of the EIF2AK4 gene cause heritable pulmonary veno-occlusive disease and/or pulmonary capillary haemangiomatosis (PVOD/PCH). We aimed to assess the effect of EIF2AK4 mutations on the clinical phenotypes and outcomes of PVOD/PCH. METHODS: We did a population-based study using clinical, functional, and haemodynamic data from the registry of the French Pulmonary Hypertension Network. We reviewed the clinical data and outcomes from all patients referred to the French Referral Centre (Pulmonary Department, Hospital Kremlin-Bicêtre, University Paris-Sud) with either confirmed or highly probable PVOD/PCH with DNA available for mutation screening (excluding patients with other risk factors of pulmonary hypertension, such as chronic respiratory diseases)...
January 10, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28087361/pulmonary-veno-occlusive-disease-characterising-a-rare-but-important-disease
#5
Charaka Hadinnapola, Nicholas W Morrell
No abstract text is available yet for this article.
January 10, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28089118/occupational-lung-diseases-from-old-and-novel-exposures-to-effective-preventive-strategies
#6
REVIEW
Paul Cullinan, Xavier Muñoz, Hille Suojalehto, Raymond Agius, Surinder Jindal, Torben Sigsgaard, Anders Blomberg, Denis Charpin, Isabella Annesi-Maesano, Mridu Gulati, Yangho Kim, Arthur L Frank, Metin Akgün, David Fishwick, Rafael E de la Hoz, Subhabrata Moitra
Occupational exposure is an important, global cause of respiratory disease. Unlike many other non-communicable lung diseases, the proximal causes of many occupational lung diseases are well understood and they should be amenable to control with use of established and effective approaches. Therefore, the risks arising from exposure to silica and asbestos are well known, as are the means of their prevention. Although the incidence of occupational lung disease has decreased in many countries, in parts of the world undergoing rapid economic transition and population growth-often with large informal and unregulated workforces-occupational exposures continue to impose a heavy burden of disease...
January 6, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28089117/respiratory-diseases-in-the-marginal-labour-sectors-a-call-to-action
#7
Subhabrata Moitra, Jesper Bælum, Nicola Murgia
No abstract text is available yet for this article.
January 6, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28065776/corrections
#8
(no author information available yet)
No abstract text is available yet for this article.
January 5, 2017: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28017640/cystic-fibrosis-a-call-for-papers-for-the-ecfs-meeting
#9
Emma Grainger
No abstract text is available yet for this article.
December 22, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28017342/will-ex-vivo-lung-perfusion-allow-a-move-towards-daytime-lung-transplantation-surgery
#10
Peter Riddell, Jim J Egan
No abstract text is available yet for this article.
December 21, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28017341/from-latent-to-patent-rethinking-prediction-of-tuberculosis
#11
Frank Cobelens, Sandra Kik, Hanif Esmail, Daniela Maria Cirillo, Christian Lienhardt, Alberto Matteelli
No abstract text is available yet for this article.
December 21, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28011037/assessment-of-safety-and-efficacy-of-long-term-treatment-with-combination-lumacaftor-and-ivacaftor-therapy-in-patients-with-cystic-fibrosis-homozygous-for-the-f508del-cftr-mutation-progress-a-phase-3-extension-study
#12
Michael W Konstan, Edward F McKone, Richard B Moss, Gautham Marigowda, Simon Tian, David Waltz, Xiaohong Huang, Barry Lubarsky, Jaime Rubin, Stefanie J Millar, David J Pasta, Nicole Mayer-Hamblett, Christopher H Goss, Wayne Morgan, Gregory S Sawicki
BACKGROUND: The 24-week safety and efficacy of lumacaftor/ivacaftor combination therapy was shown in two randomised controlled trials (RCTs)-TRAFFIC and TRANSPORT-in patients with cystic fibrosis who were aged 12 years or older and homozygous for the F508del-CFTR mutation. We aimed to assess the long-term safety and efficacy of extended lumacaftor/ivacaftor therapy in this group of patients in PROGRESS, the long-term extension of TRAFFIC and TRANSPORT. METHODS: PROGRESS was a phase 3, parallel-group, multicentre, 96-week study of patients who completed TRAFFIC or TRANSPORT in 191 sites in 15 countries...
December 20, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/28011036/a-little-cftr-can-change-a-lot-slowing-cystic-fibrosis-progression
#13
Steven M Rowe
No abstract text is available yet for this article.
December 20, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27989591/expected-effects-of-adopting-a-9-month-regimen-for-multidrug-resistant-tuberculosis-a-population-modelling-analysis
#14
Emily A Kendall, Anthony T Fojo, David W Dowdy
BACKGROUND: In May, 2016, WHO endorsed a 9 month regimen for multidrug-resistant tuberculosis that is cheaper and potentially more effective than the conventional, longer (20-24 month) therapy. We aimed to investigate the population-level implications of scaling up this new regimen. METHODS: In this population modelling analysis, we developed a dynamic transmission model to simulate the introduction of this short-course regimen as an instantaneous switch in 2016...
December 16, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27989590/effect-of-the-short-course-regimen-on-the-global-epidemic-of-multidrug-resistant-tuberculosis
#15
Giovanni Sotgiu, Giovanni Battista Migliori
No abstract text is available yet for this article.
December 15, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27866861/outcomes-after-transplantation-of-lungs-preserved-for-more-than-12-h-a-retrospective-study
#16
Jonathan C Yeung, Thorsten Krueger, Kazuhiro Yasufuku, Marc de Perrot, Andrew F Pierre, Thomas K Waddell, Lianne G Singer, Shaf Keshavjee, Marcelo Cypel
BACKGROUND: Ex-vivo lung perfusion (EVLP) can be used to extend overall lung preservation time by splitting one long cold ischaemic time into two shorter ones and interposing an additional EVLP time. We assessed the outcomes after clinical transplantation of lungs with more than 12 h of preservation time. METHODS: For this retrospective study, we searched the Toronto Lung Transplant Program database for patients who had received at least one lung transplant between Jan 1, 2006, and April 30, 2015, at a single hospital in Toronto, Canada...
November 17, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27864036/comorbidities-and-the-risk-of-mortality-in-patients-with-bronchiectasis-an-international-multicentre-cohort-study
#17
Melissa J McDonnell, Stefano Aliberti, Pieter C Goeminne, Marcos I Restrepo, Simon Finch, Alberto Pesci, Lieven J Dupont, Thomas C Fardon, Robert Wilson, Michael R Loebinger, Dusan Skrbic, Dusanka Obradovic, Anthony De Soyza, Chris Ward, John G Laffey, Robert M Rutherford, James D Chalmers
BACKGROUND: Patients with bronchiectasis often have concurrent comorbidities, but the nature, prevalence, and impact of these comorbidities on disease severity and outcome are poorly understood. We aimed to investigate comorbidities in patients with bronchiectasis and establish their prognostic value on disease severity and mortality rate. METHODS: An international multicentre cohort analysis of outpatients with bronchiectasis from four European centres followed up for 5 years was done for score derivation...
November 15, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27864033/bronchiectasis-shaking-off-its-orphan-status
#18
Paul J Torzillo
No abstract text is available yet for this article.
November 15, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27843130/reduction-of-childhood-pneumonia-mortality-in-the-sustainable-development-era
#19
Eric D McCollum, Carina King, Laura L Hammitt, Amy S Ginsburg, Tim Colbourn, Abdullah H Baqui, Katherine L O'Brien
No abstract text is available yet for this article.
November 11, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27814987/nice-approves-osimertinib-for-advanced-lung-cancer
#20
Talha Khan Burki
No abstract text is available yet for this article.
November 1, 2016: Lancet Respiratory Medicine
journal
journal
47869
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"